- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Optimizing Metastatic Colorectal Cancer Care: From Clinical Evidence to Real-World Excellence
Panelists discuss how evolving clinical evidence, real-world outcomes, and patient-reported data inform the selection, sequencing, and implementation of third-line therapies for metastatic colorectal cancer, highlighting the importance of individualized care, cross-setting collaboration, and strategies to enhance community adoption and patient quality of life.
EP. 1: Overview of Available Third-Line Options in mCRC
Panelists discuss how available third-line therapies, such as FTD/TPI, regorafenib, and others, are chosen based on survival data, safety, and patient quality of life.
Watch
EP. 2: Evidence Supporting FTD/TPI ± Bevacizumab in mCRC
Panelists discuss how the SUNLIGHT trial and real-world evidence support FTD/TPI with or without bevacizumab as an effective third-line option in metastatic colorectal cancer.
Watch
EP. 3: Efficacy of Fruquintinib and Comparisons Across Agents in mCRC
Panelists discuss how data from FRESCO-2 and other trials position fruquintinib as a strong third-line option compared with regorafenib and FTD/TPI.
Watch
EP. 4: Selecting Among Third-Line Therapies in Clinical Practice for mCRC
Panelists discuss how efficacy, safety, quality of life, and patient-specific factors drive selection among third-line therapies in metastatic colorectal cancer.
Watch
EP. 5: Leveraging Real-World Evidence in Sequencing Decisions for mCRC
Panelists discuss how RWE helps guide sequencing choices when head-to-head trial data are lacking in third-line metastatic colorectal cancer.
Watch
EP. 6: Translating Real-World Outcomes in mCRC Into Patient Conversations
Panelists discuss how real-world outcomes inform patient conversations and support shared decision-making for third-line metastatic colorectal cancer therapies.
Watch
EP. 7: Incorporating Patient-Reported Outcomes in mCRC Into Shared Decision-Making
Panelists discuss how PROs, particularly tolerability and fatigue, guide shared decision-making for third-line therapy in mCRC.
Watch
EP. 8: Real-World Evidence in mCRC: Special Populations and Safety Assessment
Panelists discuss how RWE informs treatment and safety decisions for special populations such as patients with ECOG PS 2 with metastatic colorectal cancer.
Watch
